title: Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.
abstract: Despite recent therapeutic improvements, the clinical course of diffuse large B-cell lymphoma (DLBCL) still differs considerably among patients. We conducted this retrospective multi-centre study to evaluate the impact of genomic aberrations detected using a high-density genome wide-single nucleotide polymorphism-based array on clinical outcome in a population of DLBCL patients treated with R-CHOP-21 (rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone repeated every 21 d). 166 DNA samples were analysed using the GeneChip Human Mapping 250K NspI. Genomic anomalies were analysed regarding their impact on the clinical course of 124 patients treated with R-CHOP-21. Unsupervised clustering was performed to identify genetically related subgroups of patients with different clinical outcomes. Twenty recurrent genetic lesions showed an impact on the clinical course. Loss of genomic material at 8p23.1 showed the strongest statistical significance and was associated with additional aberrations, such as 17p- and 15q-. Unsupervised clustering identified five DLBCL clusters with distinct genetic profiles, clinical characteristics and outcomes. Genetic features and clusters, associated with a different outcome in patients treated with R-CHOP, have been identified by arrayCGH.
authors.affiliation: Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
authors.forename: Marta
authors.initials: M
authors.lastname: Scandurra
authors.forename: Michael
authors.initials: M
authors.lastname: Mian
authors.forename: Timothy C
authors.initials: TC
authors.lastname: Greiner
authors.forename: Paola M V
authors.initials: PM
authors.lastname: Rancoita
authors.forename: Cassio P
authors.initials: CP
authors.lastname: De Campos
authors.forename: Wing C
authors.initials: WC
authors.lastname: Chan
authors.forename: Julie M
authors.initials: JM
authors.lastname: Vose
authors.forename: Ekaterina
authors.initials: E
authors.lastname: Chigrinova
authors.forename: Giorgio
authors.initials: G
authors.lastname: Inghirami
authors.forename: Annalisa
authors.initials: A
authors.lastname: Chiappella
authors.forename: Luca
authors.initials: L
authors.lastname: Baldini
authors.forename: Maurilio
authors.initials: M
authors.lastname: Ponzoni
authors.forename: Andres J M
authors.initials: AJ
authors.lastname: Ferreri
authors.forename: Silvia
authors.initials: S
authors.lastname: Franceschetti
authors.forename: Gianluca
authors.initials: G
authors.lastname: Gaidano
authors.forename: Santiago
authors.initials: S
authors.lastname: Montes-Moreno
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Piris
authors.forename: Fabio
authors.initials: F
authors.lastname: Facchetti
authors.forename: Alessandra
authors.initials: A
authors.lastname: Tucci
authors.forename: Josep Fr
authors.initials: JF
authors.lastname: Nomdedeu
authors.forename: Thierry
authors.initials: T
authors.lastname: Lazure
authors.forename: Olivier
authors.initials: O
authors.lastname: Lambotte
authors.forename: Silvia
authors.initials: S
authors.lastname: Uccella
authors.forename: Graziella
authors.initials: G
authors.lastname: Pinotti
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Pruneri
authors.forename: Giovanni
authors.initials: G
authors.lastname: Martinelli
authors.forename: Ken H
authors.initials: KH
authors.lastname: Young
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Tibiletti
authors.forename: Andrea
authors.initials: A
authors.lastname: Rinaldi
authors.forename: Emanuele
authors.initials: E
authors.lastname: Zucca
authors.forename: Ivo
authors.initials: I
authors.lastname: Kwee
authors.forename: Francesco
authors.initials: F
authors.lastname: Bertoni
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D055028:Comparative Genomic Hybridization; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D015398:Signal Transduction / Q000235:genetics; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone